Rickets (VDDR)

Categories: Bone diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Rickets

MalaCards integrated aliases for Rickets:

Name: Rickets 12 75 53 29 55 43 44 15 17 72
Vitamin D-Dependent Rickets 12 25 37 6 72
Vitamin D Deficiency 55 43 17 72 33
Vitamin D Hydroxylation-Deficient Rickets 12
Vitamin D Deficiency Disease 53
Vitamin-D Deficiency Rickets 53
Nutritional Rickets 53
Hypovitaminosis D 53
Active Rickets 12
Vitamin D 43
Vddr 25


External Ids:

Disease Ontology 12 DOID:10609
KEGG 37 H01143
ICD9CM 35 268.0
MeSH 44 D012279
NCIt 50 C26878
SNOMED-CT 68 41345002 68295002
ICD10 33 E55 E55.0 E55.9
UMLS 72 C0035579 C0042870 C0221468

Summaries for Rickets

MedlinePlus : 43 What is vitamin D deficiency? Vitamin D deficiency means that you are not getting enough vitamin D to stay healthy. Why do I need vitamin D and how do I get it? Vitamin D helps your body absorb calcium. Calcium is one of the main building blocks of bone. Vitamin D also has a role in your nervous, muscle, and immune systems. You can get vitamin D in three ways: through your skin, from your diet, and from supplements. Your body forms vitamin D naturally after exposure to sunlight. But too much sun exposure can lead to skin aging and skin cancer, so many people try to get their vitamin D from other sources. How much vitamin D do I need? The amount of vitamin D you need each day depends on your age. The recommended amounts, in international units (IU), are Birth to 12 months: 400 IU Children 1-13 years: 600 IU Teens 14-18 years: 600 IU Adults 19-70 years: 600 IU Adults 71 years and older: 800 IU Pregnant and breastfeeding women: 600 IU People at high risk of vitamin D deficiency may need more. Check with your health care provider about how much you need. What causes vitamin D deficiency? You can become deficient in vitamin D for different reasons: You don't get enough vitamin D in your diet You don't absorb enough vitamin D from food (a malabsorption problem) You don't get enough exposure to sunlight. Your liver or kidneys cannot convert vitamin D to its active form in the body. You take medicines that interfere with your body's ability to convert or absorb vitamin D Who is at risk of vitamin D deficiency? Some people are at higher risk of vitamin D deficiency: Breastfed infants, because human milk is a poor source of vitamin D. If you are breastfeeding, give your infant a supplement of 400 IU of vitamin D every day. Older adults, because your skin doesn't make vitamin D when exposed to sunlight as efficiently as when you were young, and your kidneys are less able to convert vitamin D to its active form. People with dark skin, which has less ability to produce vitamin D from the sun. People with disorders such as Crohn's disease or celiac disease who don't handle fat properly, because vitamin D needs fat to be absorbed. People who have obesity, because their body fat binds to some vitamin D and prevents it from getting into the blood. People who have had gastric bypass surgery People with osteoporosis People with chronic kidney or liver disease. People with hyperparathyroidism (too much of a hormone that controls the body's calcium level) People with sarcoidosis, tuberculosis, histoplasmosis, or other granulomatous disease (disease with granulomas, collections of cells caused by chronic inflammation) People with some lymphomas, a type of cancer. People who take medicines that affect vitamin D metabolism, such as cholestyramine (a cholesterol drug), anti-seizure drugs, glucocorticoids, antifungal drugs, and HIV/AIDS medicines. Talk with your health care provider if you are at risk for vitamin D deficiency. There is a blood test which can measure how much vitamin D is in your body. What problems does vitamin D deficiency cause? Vitamin D deficiency can lead to a loss of bone density, which can contribute to osteoporosis and fractures. Severe vitamin D deficiency can also lead to other diseases. In children, it can cause rickets. Rickets is a rare disease that causes the bones to become soft and bend. African American infants and children are at higher risk of getting rickets. In adults, severe vitamin D deficiency leads to osteomalacia. Osteomalacia causes weak bones, bone pain, and muscle weakness. Researchers are studying vitamin D for its possible connections to several medical conditions, including diabetes, high blood pressure, cancer, and autoimmune conditions such as multiple sclerosis. They need to do more research before they can understand the effects of vitamin D on these conditions. How can I get more vitamin D? There are a few foods that naturally have some vitamin D: Fatty fish such as salmon, tuna, and mackerel Beef liver Cheese Mushrooms Egg yolks You can also get vitamin D from fortified foods. You can check the food labels to find out whether a food has vitamin D. Foods that often have added vitamin D include Milk Breakfast cereals Orange juice Other dairy products, such as yogurt Soy drinks Vitamin D is in many multivitamins. There are also vitamin D supplements, both in pills and a liquid for babies. If you have vitamin D deficiency, the treatment is with supplements. Check with your health care provider about how much you need to take, how often you need to take it, and how long you need to take it. Can too much vitamin D be harmful? Getting too much vitamin D (known as vitamin D toxicity) can be harmful. Signs of toxicity include nausea, vomiting, poor appetite, constipation, weakness, and weight loss. Excess vitamin D can also damage the kidneys. Too much vitamin D also raises the level of calcium in your blood. High levels of blood calcium (hypercalcemia) can cause confusion, disorientation, and problems with heart rhythm. Most cases of vitamin D toxicity happen when someone overuses vitamin D supplements. Excessive sun exposure doesn't cause vitamin D poisoning because the body limits the amount of this vitamin it produces.

MalaCards based summary : Rickets, also known as vitamin d-dependent rickets, is related to vitamin d-dependent rickets, type 2a and hypophosphatemic rickets, autosomal dominant, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Rickets is VDR (Vitamin D Receptor), and among its related pathways/superpathways are Steroid biosynthesis and Endocrine and other factor-regulated calcium reabsorption. The drugs Ribavirin and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and breast, and related phenotypes are homeostasis/metabolism and growth/size/body region

Disease Ontology : 12 A bone remodeling disease that has material basis in impaired mineralization or calcification of bones before epiphyseal closure due to deficiency or impaired metabolism of vitamin D, phosphorus or calcium which results in softening and deformity located in bone.

Genetics Home Reference : 25 Vitamin D-dependent rickets is a disorder of bone development that leads to softening and weakening of the bones (rickets). There are several forms of the condition that are distinguished primarily by their genetic causes: type 1A (VDDR1A), type 1B (VDDR1B), and type 2A (VDDR2A). There is also evidence of a very rare form of the condition, called type 2B (VDDR2B), although not much is known about this form. The signs and symptoms of vitamin D-dependent rickets begin within months after birth, and most are the same for all types of the condition. The weak bones often cause bone pain and delayed growth and have a tendency to fracture. When affected children begin to walk, they may develop abnormally curved (bowed) legs because the bones are too weak to bear weight. Impaired bone development also results in widening of the areas near the ends of bones where new bone forms (metaphyses), especially in the knees, wrists, and ribs. Some people with vitamin D-dependent rickets have dental abnormalities such as thin tooth enamel and frequent cavities. Poor muscle tone (hypotonia) and muscle weakness are also common in this condition, and some affected individuals develop seizures. In vitamin D-dependent rickets, there is an imbalance of certain substances in the blood. An early sign in all types of the condition is low levels of the mineral calcium (hypocalcemia), which is essential for the normal formation of bones and teeth. Affected individuals also develop high levels of a hormone involved in regulating calcium levels called parathyroid hormone (PTH), which leads to a condition called secondary hyperparathyroidism. Low levels of a mineral called phosphate (hypophosphatemia) also occur in affected individuals. Vitamin D-dependent rickets types 1 and 2 can be grouped by blood levels of a hormone called calcitriol, which is the active form of vitamin D; individuals with VDDR1A and VDDR1B have abnormally low levels of calcitriol and individuals with VDDR2A and VDDR2B have abnormally high levels. Hair loss (alopecia) can occur in VDDR2A, although not everyone with this form of the condition has alopecia. Affected individuals can have sparse or patchy hair or no hair at all on their heads. Some affected individuals are missing body hair as well.

NIH Rare Diseases : 53 Rickets is a condition that causes children to have soft, weak bones. It usually occurs when children do not get enough vitamin D, which helps growing bones absorb important nutrients. Vitamin D comes from sunlight and food. Skin produces vitamin D in response to the sun's rays. Some foods also contain vitamin D, including fortified dairy products and cereals, and some kinds of fish.

KEGG : 37
Rickets is the failure of growing bone to mineralize. Many skeletal and radiographic changes can occur because of the lack of calcified osteoid and the buildup of unossified cartilage. Vitamin D-dependent rickets type I results from abnormalities in the gene coding for 25(OH)D3-1-alpha-hydroxylase and vitamin D 25-hydroxylase, and type II results from defective vitamin D receptors. Both diseases are rare autosomal recessive disorders characterized by hypocalcemia, secondary hyperparathyroidism and early onset severe rickets.

Wikipedia : 75 Rickets is a condition that results in weak or soft bones in children. Symptoms include bowed legs,... more...

Related Diseases for Rickets

Diseases related to Rickets via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1579)
# Related Disease Score Top Affiliating Genes
1 vitamin d-dependent rickets, type 2a 34.9 VDR PHEX CYP27B1
2 hypophosphatemic rickets, autosomal dominant 34.6 SLC34A3 PHEX FGF23
3 hereditary hypophosphatemic rickets 34.6 SLC34A3 SLC34A1
4 hypocalcemic vitamin d-dependent rickets 34.3 CYP2R1 CYP27B1
5 autosomal recessive hypophosphatemic rickets 34.1 PHEX FGF23 ENPP1 DMP1
6 arterial calcification of infancy 33.0 PHEX FGF23 ENPP1
7 hypophosphatemic rickets, x-linked dominant 32.7 SLC34A3 SLC34A1 PTH PHEX FGF23 DMP1
8 ossification of the posterior longitudinal ligament of spine 32.4 ENPP1 BGLAP
9 hypophosphatemic rickets, x-linked recessive 32.3 VDR SLC34A3 SLC34A1 PHEX FGF23 ENPP1
10 renal osteodystrophy 31.8 VDR PTH FGF23 BGLAP
11 hypophosphatasia 31.8 PHEX ENPP1 ALPP ALPL
12 hypophosphatemic rickets with hypercalciuria, hereditary 31.8 SLC34A3 SLC34A1 PTH PHEX FGF23 ENPP1
13 glucocorticoid-induced osteoporosis 31.6 PTH BGLAP
14 axial osteomalacia 31.3 PTH BGLAP
15 osteomalacia 30.8 VDR PTH PHEX FGF23 DMP1 BGLAP
16 nephrolithiasis, calcium oxalate 30.7 VDR SLC34A1 CLCN5
17 osteoporosis, juvenile 30.6 PTH GC BGLAP
18 calcinosis 30.5 PHEX FGF23 ENPP1
19 hypercalciuria, absorptive, 2 30.5 VDR SLC34A3 CLCN5
20 enthesopathy 30.5 PHEX FGF23 DMP1
21 opsismodysplasia 30.4 PHEX FGF23
22 hypophosphatasia, adult 30.4 PTH ENPP1 BGLAP ALPL
23 familial tumoral calcinosis 30.3 PHEX FGF23
24 raine syndrome 30.3 FGF23 DMP1
25 oncogenic osteomalacia 30.2 PTH PHEX FGF23 DMP1
26 bone resorption disease 29.8 VDR PTH BGLAP
27 hypocalcemia, autosomal dominant 1 29.8 VDR PTH FGF23
28 hypervitaminosis d 29.8 VDR PTH FGF23 CYP27B1
29 osteitis fibrosa 29.7 PTH BGLAP
30 spondylosis 29.7 VDR PTH
31 hypercalcemia, infantile, 1 29.7 VDR PTH
32 hyperparathyroidism 29.7 VDR PTH PHEX FGF23 CYP27B1 BGLAP
33 idiopathic hypercalciuria 29.6 VDR SLC34A3 CLCN5 BGLAP
34 nephrocalcinosis 29.6 SLC34A3 SLC34A1 PTH PHEX CLCN5
35 parathyroid adenoma 29.5 VDR PTH BGLAP
36 kidney disease 29.4 VDR PTH FGF23 CLCN5
37 chondrocalcinosis 29.4 ENPP1 ALPL
38 calciphylaxis 29.4 VDR PTH FGF23
39 hyperphosphatemia 29.4 VDR SLC34A1 PTH PHEX FGF23
40 pulmonary alveolar microlithiasis 29.1 SLC34A3 SLC34A1 PTH FGF23
41 hypoparathyroidism 29.0 PTH FGF23 BGLAP ALPP
42 secondary hyperparathyroidism of renal origin 28.7 VDR PTH FGF23 CYP27B1 BGLAP
43 primary hyperparathyroidism 28.7 VDR PTH FGF23 BGLAP ALPP
44 parathyroid gland disease 28.5 VDR PTH FGF23 BGLAP
45 hypophosphatemia 28.2 SLC34A3 SLC34A1 PTH PHEX FGF23 ENPP1
46 bone disease 28.2 VDR SLC34A3 PTH FGF23 BGLAP ALPP
47 mineral metabolism disease 28.1 VDR SLC34A3 PTH PHEX FGF23 CLCN5
48 phosphorus metabolism disease 27.4 VDR SLC34A3 SLC34A1 PTH PHEX FGF23
49 osteoporosis 26.3 VDR SLC34A1 PTH GC FGF23 CYP27B1
50 vitamin d hydroxylation-deficient rickets, type 1a 12.7

Comorbidity relations with Rickets via Phenotypic Disease Network (PDN):

Acute Cystitis Deficiency Anemia

Graphical network of the top 20 diseases related to Rickets:

Diseases related to Rickets

Symptoms & Phenotypes for Rickets

UMLS symptoms related to Rickets:

back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Rickets:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 ALPL CLCN5 CYP27B1 CYP2R1 DMP1 ENPP1
2 growth/size/body region MP:0005378 10.06 ALPL CLCN5 CYP27B1 DMP1 ENPP1 FGF23
3 cardiovascular system MP:0005385 9.98 ALPL DMP1 ENPP1 FGF23 PHEX PTH
4 craniofacial MP:0005382 9.95 ALPL CLCN5 CYP27B1 DMP1 PHEX PTH
5 endocrine/exocrine gland MP:0005379 9.91 ALPL CYP27B1 FGF23 GC PHEX PTH
6 limbs/digits/tail MP:0005371 9.76 ALPL CYP27B1 DMP1 ENPP1 FGF23 PHEX
7 renal/urinary system MP:0005367 9.61 CLCN5 CYP27B1 DMP1 ENPP1 FGF23 PHEX
8 skeleton MP:0005390 9.44 ALPL CLCN5 CYP27B1 CYP2R1 DMP1 ENPP1

Drugs & Therapeutics for Rickets

Drugs for Rickets (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 688)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ribavirin Approved Phase 4 36791-04-5 37542
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
Dinoprostone Approved Phase 4 363-24-6 5280360
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Linagliptin Approved Phase 4 668270-12-0 10096344
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
Rufinamide Approved Phase 4 106308-44-5 129228
Nitrazepam Approved Phase 4 146-22-5 4506
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
Stiripentol Approved Phase 4 49763-96-4
Clobazam Approved, Illicit Phase 4 22316-47-8 2789
Vigabatrin Approved Phase 4 60643-86-9, 68506-86-5 5665
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
Topiramate Approved Phase 4 97240-79-4 5284627
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
Ethosuximide Approved Phase 4 77-67-8 3291
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
Ethanol Approved Phase 4 64-17-5 702
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Racepinephrine Approved Phase 4 329-65-7 838
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
Phylloquinone Approved, Investigational Phase 4 84-80-0
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
Altretamine Approved Phase 4 645-05-6 2123
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
Copper Approved, Investigational Phase 4 7440-50-8 27099
Ezetimibe Approved Phase 4 163222-33-1 150311
Adalimumab Approved Phase 4 331731-18-1 16219006
Etanercept Approved, Investigational Phase 4 185243-69-0
Lactulose Approved Phase 4 4618-18-2 11333
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Pamidronate Approved Phase 4 40391-99-9 4674
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
Demeclocycline Approved Phase 4 127-33-3 5311063
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
Sage Approved Phase 4
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Saxagliptin Approved Phase 4 361442-04-8 11243969

Interventional clinical trials:

(show top 50) (show all 2521)
# Name Status NCT ID Phase Drugs
1 Optimal Initial and Maintenance Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Thai Adults: A Randomized, Double-blinded Dose-comparison Study Unknown status NCT03228862 Phase 4 Ergocalciferol
2 Does Administration of Vitamin D in African Americans With Hypovitaminosis D and Type 2 DM Improve Inflammatory Markers of Cardiovascular Disease? Unknown status NCT01153243 Phase 4 Ergocalciferol;Placebo pill
3 Correction of Vitamin D Deficiency to Prevent Postoperative Hypocalcemia After Thyroidectomy Unknown status NCT01632514 Phase 4 Cholecalciferol
4 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
5 The Impacts of Vitamin D Supplementation on Glucose Metabolism in Chinese Women With Vitamin D Deficiency and Former Gestational Diabetes Mellitus:A Randomised Control Trial Unknown status NCT03138616 Phase 4 vitamin D
6 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
7 Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis: a Double-blind Randomised Controlled Trial Unknown status NCT02507843 Phase 4 Cholecalciferol;Placebo
8 Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome Unknown status NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
9 Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial Unknown status NCT02598635 Phase 4 Cholecalciferol;Placebo
10 Intervention Study Measuring Inflammatory Cytokine Levels in the Serum of Patients Who Underwent an Acute MI, and the Influence of Vitamin D on These Levels Unknown status NCT01115842 Phase 4 Vitamin D
11 Effect of Vitamin D Supplementation on Postoperative Pain and Sedation-agitation Unknown status NCT02664857 Phase 4 Vitamin D;Placebo
12 Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension (VDATH) Unknown status NCT01472796 Phase 4 Tekturna(Aliskiren) plus placebo
13 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
14 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 and Normal Protein Diet Virus Low Protein Diet in the Treatment of CKD-MBD and Malnutrition for Progressive CKD Patients Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
15 Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
16 Effect of Vitamin d Supplementation on the Control of Persistent Asthma in Children at Dr George Mukhari Academic Hospital, Pretoria, South Africa Unknown status NCT02053402 Phase 4 Vitamin D
17 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
18 Vitamin D Concentrations and Their Effect on Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
19 Optimal Substitution Dose of the Vitamin D During Winter Time in Patient With Inflammatory Bowel Diseases (IBD) Unknown status NCT02958501 Phase 4 Colecalciferol
20 the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes Unknown status NCT01876563 Phase 4
21 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
22 Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D Unknown status NCT01442272 Phase 4 Hidroferol®;Paricalcitol: Zemplar®;Habitual medication
23 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
24 The Assessment of the Effect of Vitamin D Supplementation on the Serum of AGES and Endothelialy Factors and Gene Expression of Glyoxalase Enzyme and YKL-40 Factor in PBMC Cells in the Patients With Type 2 Diabetes . Unknown status NCT03008057 Phase 4
25 Effect of Vitamin D Supplementation on Bone Turnover Markers During Tenofovir-Emtricitibine Pre-Exposure Prophylaxis in Men Who Have Sex With Men; A Sub-study of CCTG 595 Unknown status NCT02367599 Phase 4 Vitamin D Supplement
26 Effect of Vitamin D Supplementation in Young Children With Acute Lower Respiratory Tract Infection at Dr George Mukhari Academic Hospital, Pretoria, South Africa Unknown status NCT02054182 Phase 4 Vitamin D
27 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
28 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
29 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
30 Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
31 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
32 An Open-label Study of Combination of Cinacalcet and Active Vitamin D Analogue in the Management of Severe Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
33 Pilot Study of the Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection Unknown status NCT01343225 Phase 4 atripla;darunavir ritonavir raltegravir
34 Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression Unknown status NCT01390662 Phase 4
35 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis (EVIDENT Study): a Randomized, Double Blind, Controlled Trial Unknown status NCT02169570 Phase 4
36 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis in the National Institute of Respiratory Diseases Unknown status NCT02464683 Phase 4
37 Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD Unknown status NCT01820832 Phase 4 Calcitriol
38 A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy Unknown status NCT02322099 Phase 4 Alendronate;Placebo;Tenofovir disoproxil
39 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
40 A Double Blind Randomized Control Trial to Study the Effect of Long Term Vitamin D Supplementation on Peripheral Insulin Sensitivity in Apparently Healthy Middle Aged Centrally Obese Adults Unknown status NCT01052181 Phase 4 Cholecalciferol;placebo
41 Effect of Multi-vitamins With Minerals on Uric Acid Metabolism in Subjects With Hyperuricemia: A Randomized, Double-blinded, Placebo-controlled Trail Unknown status NCT03218709 Phase 4
42 Asthma and Vitamin D (a Clinical Pilot Study) Unknown status NCT00712205 Phase 4 Placebo;Calcitriol
43 A Randomized Study Comparing Goserelin or Expectant Management Following Laparoscopic Surgery for Advanced Endometriosis Unknown status NCT00654524 Phase 4 gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin
44 Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
45 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
46 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
47 Regulation of Bone Mineralization in Renal Osteodystrophy Unknown status NCT01799317 Phase 4 Vitamin D2
48 Evaluation of Potential Benefits of Using Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Unknown status NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
49 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
50 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1

Search NIH Clinical Center for Rickets

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Calcifediol Anhydrous
Cod Liver Oil

Cochrane evidence based reviews: rickets

Genetic Tests for Rickets

Genetic tests related to Rickets:

# Genetic test Affiliating Genes
1 Rickets 29

Anatomical Context for Rickets

MalaCards organs/tissues related to Rickets:

Bone, Kidney, Breast, Heart, Liver, Prostate, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Rickets:


Publications for Rickets

Articles related to Rickets:

(show top 50) (show all 6868)
# Title Authors PMID Year
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. 38 17
31104833 2019
Burosumab treatment of children with X-linked hypophosphataemic rickets. 38 17
31104830 2019
Association between vitamin D supplementation and mortality: systematic review and meta-analysis. 17
31405892 2019
Vitamin D Supplementation and Prevention of Type 2 Diabetes. 17
31173679 2019
The effect of vitamin D3 on blood pressure in people with vitamin D deficiency: A system review and meta-analysis. 17
31083159 2019
Phosphaturia in kidney stone formers: Still an enigma. 17
31122608 2019
On the genetic determinants of hypovitaminosis D. 17
31284259 2019
Genetic disorders and defects in vitamin d action. 9 38
20511055 2010
[Bone and joint diseases in children. Phosphaturic hormone, FGF23, and bone metabolism]. 9 38
20513948 2010
Physiological role of alkaline phosphatase explored in hypophosphatasia. 9 38
20392236 2010
A novel missense mutation (C84R) in a patient with type II vitamin d-dependent rickets. 9 38
20146166 2010
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. 9 38
19965919 2010
Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from a novel missense mutation in the DNA-binding domain of the vitamin D receptor. 9 38
19815438 2010
Genetic causes of hypercalciuric nephrolithiasis. 9 38
18446382 2009
Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. 9 38
19555782 2009
Hereditary vitamin D resistant rickets: identification of a novel splice site mutation in the vitamin D receptor gene and successful treatment with oral calcium therapy. 9 38
19523546 2009
Predisposition to vitamin D deficiency osteomalacia and rickets in females is linked to their 25(OH)D and calcium intake rather than vitamin D receptor gene polymorphism. 9 38
19094076 2009
Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice. 9 38
19609735 2009
Chronic recurrent multifocal osteomyelitis mimicked in childhood hypophosphatasia. 9 38
19335222 2009
Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. 9 38
18974917 2009
Emerging topics in pediatric bone and mineral disorders 2008. 9 38
19615558 2009
Novel human pathological mutations. Gene symbol: PHEX. Disease: rickets, hypophosphataemic. 9 38
19309785 2009
Compound heterozygous mutations in the vitamin D receptor in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia. 9 38
19049339 2009
Dentin noncollagenous matrix proteins in familial hypophosphatemic rickets. 9 38
18701809 2009
Hypophosphatemia: the common denominator of all rickets. 9 38
19504043 2009
Mutations in the vitamin D receptor gene in four patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets. 9 38
19169476 2008
Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. 9 38
18541802 2008
Rickets in the Middle East: role of environment and genetic predisposition. 9 38
18285415 2008
FGF23 is elevated in Gambian children with rickets. 9 38
18234575 2008
Ligand-independent regulation of the hairless promoter by vitamin D receptor. 9 38
18266815 2008
Bullous congenital ichthyosiform erythroderma associated with hypocalcemic vitamin D-resistant rickets. 9 38
18429807 2008
Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. 9 38
18037620 2008
Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. 9 38
18172553 2008
Vitamin D receptor gene polymorphisms in Turkish children with vitamin D deficient rickets. 9 38
18365588 2008
A novel Phex mutation with defective glycosylation causes hypophosphatemia and rickets in mice. 9 38
17710565 2008
Genetics of hypercalciuric nephrolithiasis: renal stone disease. 9 38
17872384 2007
[Role of vitamin D3 in arterial blood pressure control]. 9 38
18293857 2007
[Phosphatonin]. 9 38
17906412 2007
[Pathophysiology in rickets/osteomalacia]. 9 38
17906401 2007
Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency. 9 38
17488797 2007
Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. 9 38
17565275 2007
Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. 9 38
17635819 2007
Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. 9 38
17395561 2007
[Fibroblast growth factor (FGF) 23 works as a phosphate-regulating hormone and is involved in the pathogenesis of several disorders of phosphate metabolism]. 9 38
17657990 2007
FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. 9 38
17227222 2007
A unique insertion/duplication in the VDR gene that truncates the VDR causing hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. 9 38
17078924 2007
Vitamin D receptor polymorphism among rickets children in Mongolia. 9 38
17202743 2007
The retinoid X receptor ligand restores defective signalling by the vitamin D receptor. 9 38
16936639 2006
[From gene to disease; hypophosphataemic rickets and the PHEX gene]. 9 38
17061325 2006
Vitamin D receptor polymorphism in nutritional rickets. 9 38
17551469 2006

Variations for Rickets

ClinVar genetic disease variations for Rickets:

6 (show top 50) (show all 102)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 VDR NM_001017535.1(VDR): c.2T> C (p.Met1Thr) single nucleotide variant drug response rs2228570 12:48272895-48272895 12:47879112-47879112
2 VDR NM_001017535.1(VDR): c.909C> T (p.Ala303=) single nucleotide variant Conflicting interpretations of pathogenicity rs12721365 12:48240233-48240233 12:47846450-47846450
3 VDR NM_001017535.1(VDR): c.*1865G> A single nucleotide variant Uncertain significance rs11540149 12:48236664-48236664 12:47842881-47842881
4 VDR NM_001017535.1(VDR): c.*1805A> T single nucleotide variant Uncertain significance rs886049426 12:48236724-48236724 12:47842941-47842941
5 VDR NM_001017535.1(VDR): c.*437C> G single nucleotide variant Uncertain significance rs11574119 12:48238092-48238092 12:47844309-47844309
6 VDR NM_001017535.1(VDR): c.*409G> A single nucleotide variant Uncertain significance rs11574118 12:48238120-48238120 12:47844337-47844337
7 VDR NM_001017535.1(VDR): c.*405G> T single nucleotide variant Uncertain significance rs886049432 12:48238124-48238124 12:47844341-47844341
8 VDR NM_001017535.1(VDR): c.*387C> G single nucleotide variant Uncertain significance rs886049433 12:48238142-48238142 12:47844359-47844359
9 VDR NM_001017535.1(VDR): c.-146C> T single nucleotide variant Uncertain significance rs886049439 12:48293682-48293682 12:47899899-47899899
10 VDR NM_001017535.1(VDR): c.-202T> C single nucleotide variant Uncertain significance rs752094022 12:48293738-48293738 12:47899955-47899955
11 VDR NM_001017535.1(VDR): c.-250G> A single nucleotide variant Uncertain significance rs886049440 12:48298782-48298782 12:47904999-47904999
12 CYP27B1 NM_000785.4(CYP27B1): c.*426_*428dup duplication Uncertain significance rs886049722 12:58156497-58156499 12:57762714-57762716
13 CYP27B1 NM_000785.4(CYP27B1): c.*295G> A single nucleotide variant Uncertain significance rs886049724 12:58156630-58156630 12:57762847-57762847
14 CYP27B1 NM_000785.4(CYP27B1): c.*76G> A single nucleotide variant Uncertain significance rs147119803 12:58156849-58156849 12:57763066-57763066
15 CYP27B1 NM_000785.4(CYP27B1): c.1385A> T (p.Glu462Val) single nucleotide variant Uncertain significance rs886049725 12:58157422-58157422 12:57763639-57763639
16 CYP27B1 NM_000785.4(CYP27B1): c.348C> T (p.His116=) single nucleotide variant Uncertain significance rs372771210 12:58159828-58159828 12:57766045-57766045
17 CYP27B1 NM_000785.4(CYP27B1): c.-22C> G single nucleotide variant Uncertain significance rs146281435 12:58160846-58160846 12:57767063-57767063
18 VDR NM_001017535.1(VDR): c.*298C> T single nucleotide variant Uncertain significance rs886049434 12:48238231-48238231 12:47844448-47844448
19 VDR NM_001017535.1(VDR): c.1131C> T (p.His377=) single nucleotide variant Uncertain significance rs201868713 12:48238682-48238682 12:47844899-47844899
20 VDR NM_001017535.1(VDR): c.908-14A> G single nucleotide variant Uncertain significance rs11574107 12:48240248-48240248 12:47846465-47846465
21 VDR NM_001017535.1(VDR): c.889G> A (p.Val297Ile) single nucleotide variant Uncertain significance rs144756403 12:48240458-48240458 12:47846675-47846675
22 VDR NM_001017535.1(VDR): c.755+13T> C single nucleotide variant Uncertain significance rs768024598 12:48249400-48249400 12:47855617-47855617
23 VDR NM_001017535.1(VDR): c.146+9dup duplication Uncertain significance rs748166237 12:48272742-48272742 12:47878959-47878959
24 VDR NM_001017535.1(VDR): c.*2974A> T single nucleotide variant Uncertain significance rs11574139 12:48235555-48235555 12:47841772-47841772
25 VDR NM_001017535.1(VDR): c.*2973G> A single nucleotide variant Uncertain significance rs760268626 12:48235556-48235556 12:47841773-47841773
26 VDR NM_001017535.1(VDR): c.*2900A> C single nucleotide variant Uncertain significance rs527373238 12:48235629-48235629 12:47841846-47841846
27 VDR NM_001017535.1(VDR): c.*2658dup duplication Uncertain significance rs886049413 12:48235871-48235871 12:47842088-47842088
28 VDR NM_001017535.1(VDR): c.*2413G> C single nucleotide variant Uncertain significance rs886049414 12:48236116-48236116 12:47842333-47842333
29 VDR NM_001017535.1(VDR): c.*2328C> G single nucleotide variant Uncertain significance rs770829205 12:48236201-48236201 12:47842418-47842418
30 VDR NM_001017535.1(VDR): c.*2263G> A single nucleotide variant Uncertain significance rs886049417 12:48236266-48236266 12:47842483-47842483
31 VDR NM_001017535.1(VDR): c.*2227G> A single nucleotide variant Uncertain significance rs138753910 12:48236302-48236302 12:47842519-47842519
32 VDR NM_001017535.1(VDR): c.*2226C> T single nucleotide variant Uncertain significance rs11574136 12:48236303-48236303 12:47842520-47842520
33 VDR NM_001017535.1(VDR): c.*1179del deletion Uncertain significance rs530894692 12:48237350-48237350 12:47843567-47843567
34 VDR NM_001017535.1(VDR): c.*877C> G single nucleotide variant Uncertain significance rs556844112 12:48237652-48237652 12:47843869-47843869
35 VDR NM_001017535.1(VDR): c.*534T> C single nucleotide variant Uncertain significance rs886049431 12:48237995-48237995 12:47844212-47844212
36 VDR NM_001017535.1(VDR): c.*184T> G single nucleotide variant Uncertain significance rs11574116 12:48238345-48238345 12:47844562-47844562
37 VDR NM_001017535.1(VDR): c.*111C> A single nucleotide variant Uncertain significance rs886049435 12:48238418-48238418 12:47844635-47844635
38 VDR NM_001017535.1(VDR): c.*70C> T single nucleotide variant Uncertain significance rs886049436 12:48238459-48238459 12:47844676-47844676
39 VDR NM_001017535.1(VDR): c.1134G> T (p.Leu378=) single nucleotide variant Uncertain significance rs199583004 12:48238679-48238679 12:47844896-47844896
40 VDR NM_001017535.1(VDR): c.1048G> A (p.Ala350Thr) single nucleotide variant Uncertain significance rs148856375 12:48238765-48238765 12:47844982-47844982
41 VDR NM_001017535.1(VDR): c.*1319C> T single nucleotide variant Uncertain significance rs11574131 12:48237210-48237210 12:47843427-47843427
42 VDR NM_001017535.1(VDR): c.*1235_*1239CCAGC[4] short repeat Uncertain significance rs11574130 12:48237280-48237284 12:47843497-47843501
43 VDR NM_001017535.1(VDR): c.*1178A> C single nucleotide variant Uncertain significance rs886049428 12:48237351-48237351 12:47843568-47843568
44 VDR NM_001017535.1(VDR): c.*827C> T single nucleotide variant Uncertain significance rs886049430 12:48237702-48237702 12:47843919-47843919
45 VDR NM_001017535.1(VDR): c.*748T> G single nucleotide variant Uncertain significance rs11574124 12:48237781-48237781 12:47843998-47843998
46 VDR NM_001017535.1(VDR): c.*408T> C single nucleotide variant Uncertain significance rs112308011 12:48238121-48238121 12:47844338-47844338
47 VDR NM_001017535.1(VDR): c.*97G> A single nucleotide variant Uncertain significance rs548542386 12:48238432-48238432 12:47844649-47844649
48 VDR NM_001017535.1(VDR): c.1152C> A (p.Ile384=) single nucleotide variant Uncertain significance rs753086299 12:48238661-48238661 12:47844878-47844878
49 VDR NM_001017535.1(VDR): c.945G> T (p.Lys315Asn) single nucleotide variant Uncertain significance rs886049437 12:48240197-48240197 12:47846414-47846414
50 VDR NM_001017535.1(VDR): c.278-5C> T single nucleotide variant Uncertain significance rs551270527 12:48251476-48251476 12:47857693-47857693

Expression for Rickets

Search GEO for disease gene expression data for Rickets.

Pathways for Rickets

Pathways related to Rickets according to KEGG:

# Name Kegg Source Accession
1 Steroid biosynthesis hsa00100
2 Endocrine and other factor-regulated calcium reabsorption hsa04961
3 Mineral absorption hsa04978

Pathways related to Rickets according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
Show member pathways
12.34 GC ENPP1 CYP2R1 CYP27B1
Show member pathways
3 11.53 VDR SLC34A3 SLC34A1 PTH FGF23 CYP27B1
4 11.36 PTH ENPP1 ALPL
7 11.04 VDR CYP27B1
Show member pathways
9 10.61 ALPP ALPL
10 10.58 PTH FGF23 BGLAP
11 10.02 VDR PTH GC CYP2R1 CYP27B1

GO Terms for Rickets

Cellular components related to Rickets according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 PTH GC FGF23 ENPP1 DMP1 BGLAP
2 vesicle GO:0031982 8.8 SLC34A3 SLC34A1 BGLAP

Biological processes related to Rickets according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 skeletal system development GO:0001501 9.85 VDR PTH PHEX BGLAP ALPL
2 ossification GO:0001503 9.76 SLC34A1 DMP1 BGLAP
3 cellular response to vitamin D GO:0071305 9.67 PHEX FGF23 BGLAP
4 cellular response to parathyroid hormone stimulus GO:0071374 9.65 SLC34A1 PHEX FGF23
5 biomineral tissue development GO:0031214 9.65 PHEX ENPP1 DMP1 BGLAP ALPL
6 response to cadmium ion GO:0046686 9.63 SLC34A1 PTH
7 decidualization GO:0046697 9.63 VDR CYP27B1
8 calcium ion transport GO:0006816 9.62 VDR CYP27B1
9 response to lead ion GO:0010288 9.62 SLC34A1 PTH
10 regulation of bone mineralization GO:0030500 9.62 FGF23 ENPP1 CYP27B1 BGLAP
11 phosphate-containing compound metabolic process GO:0006796 9.61 FGF23 ENPP1
12 positive regulation of keratinocyte differentiation GO:0045618 9.61 VDR CYP27B1
13 phosphate ion homeostasis GO:0055062 9.61 SLC34A1 PTH FGF23
14 response to magnesium ion GO:0032026 9.6 SLC34A1 FGF23
15 response to growth hormone GO:0060416 9.59 SLC34A1 PHEX
16 phosphate ion transport GO:0006817 9.58 SLC34A3 SLC34A1
17 bone mineralization GO:0030282 9.58 PHEX CYP27B1 BGLAP
18 vitamin metabolic process GO:0006766 9.57 CYP2R1 CYP27B1
19 sodium-dependent phosphate transport GO:0044341 9.56 SLC34A3 SLC34A1
20 response to parathyroid hormone GO:0071107 9.55 SLC34A1 PTH
21 vitamin D catabolic process GO:0042369 9.54 FGF23 CYP27B1
22 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.54 VDR FGF23 CYP27B1
23 response to sodium phosphate GO:1904383 9.52 PHEX FGF23
24 calcitriol biosynthetic process from calciol GO:0036378 9.51 CYP2R1 CYP27B1
25 cellular phosphate ion homeostasis GO:0030643 9.46 SLC34A3 SLC34A1 FGF23 ENPP1
26 response to vitamin D GO:0033280 9.35 PTH PHEX CYP27B1 BGLAP ALPL
27 vitamin D metabolic process GO:0042359 9.02 VDR GC FGF23 CYP2R1 CYP27B1

Molecular functions related to Rickets according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:phosphate symporter activity GO:0005436 9.26 SLC34A3 SLC34A1
2 vitamin D binding GO:0005499 9.16 VDR GC
3 sodium-dependent phosphate transmembrane transporter activity GO:0015321 8.96 SLC34A3 SLC34A1
4 alkaline phosphatase activity GO:0004035 8.62 ALPP ALPL

Sources for Rickets

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....